Madrigal (MDGL) Q3 2026 Earnings Call Transcript

Madrigal Pharmaceuticals reported Q3 2026 net revenue of $431.3 million, up 50% year over year, and net income of $55.4 million—its first profitable quarter since Rezdiffra’s launch—versus a $114.2 million loss a year earlier. Year-to-date Rezdiffra sales reached $1.1 billion, with 55,850 active patients, nearly double the year-ago count; management said the F2/F3 market exceeded 530,000 patients and is expected to grow more than 30% in 2026. The company ended the quarter with $961.8 million in cash and marketable securities and expects a late-2027 readout for its MAESTRO-NASH OUTCOMES trial, while cautioning that near-term profitability may fluctuate with investment timing.

Analysis

MDGL’s key debate is whether diagnosis expansion converts into durable treated-patient growth—not the headline market size. The “1% penetrated” framing depends on two low, company-estimated rates multiplying together; it is not evidence that the remaining theoretical pool is readily addressable. Watch active patients, persistence, and new-prescriber depth against sales: if revenue growth increasingly relies on higher net price or contracting rather than patient adds, the launch thesis weakens.

Near term, the first profitable quarter is a poor run-rate anchor. Rising commercial spend, Q1 seasonality, and Medicare Part D contracting from 2027 could produce earnings volatility and higher gross-to-net deductions even if demand remains healthy. Roche royalties also mean sales growth will not translate one-for-one into retained economics. The market may underweight that margin bridge while focusing on top-line acceleration.

Over 1–3 months, verify patient trends and real-world evidence independently; company-sponsored abstracts can support adoption but do not establish clinical-outcome benefit. The major 6–18 month catalyst is Medicare contracting and execution in new specialties. The larger binary risk sits beyond that horizon: the event-driven F4c readout is now late 2027, and the additional CSPH trial adds cost before it adds evidence. A delay, weak outcome signal, or FDA disagreement on trial/label implications would challenge the expansion premium. GLP-1 use may expand diagnosis and act as a combination opportunity, but it is not proof that Rezdiffra is insulated from future competitive substitution.

Key Decisions for Investors

• Do not chase the earnings print without a valuation and positioning check. Maintain a conditional long bias only if subsequent quarters show active-patient growth tracking or exceeding revenue growth and gross-to-net remains controlled; reduce exposure if patient adds decelerate for two consecutive quarters or net sales growth materially outpaces active-patient growth.
• Track 2027 Medicare Part D contract terms and the realized gross-to-net ratio as the key near-term margin catalyst. Reassess if deductions move beyond management’s stated range or access concessions fail to produce incremental patient volume.
• Treat late-2027 F4c outcomes as a major binary catalyst, not near-term base-case revenue. Size exposure for a potential trial delay or negative result; protocol alignment with FDA and continued event accrual are watch items, not proof of success.
• Avoid shorting GLP-1 exposure solely on this call: the plausible second-order effect is category education and combination use, while substitution risk remains a longer-term monitor.